Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0095

Congress meeting · Dr. Andrea Abbott

14 Jan 2026 · In person · Dr. Andrea Abbott, Memorial Sloan Kettering · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0095—

Capture insight from this engagement

Location: Hospital La Paz
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Sequencing after progression

Scientific content used

irAE management guide
VOYAGE-1 pivotal data summary

Questions raised

What was the median PD-L1 testing turnaround in the pivotal trial sites?

Notes

Congress meeting with pathologist at Hospital La Paz. Discussed sequencing after progression.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 4
Depth of exchange: 1
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0095

Audit history (0)

All create, update and approval events for this record

No audit events in sample data